Abdi Ibrahim Ilaç Sanayi ve Ticaret A.S. manufactures and markets pharmaceuticals for customers in Turkey and internationally. It offers antianemic, antibacterial/antiviral, gastrointestinal, nervous system, ophthalmic, and urogenital system drugs; vitamins and minerals; CANMAb, a biosimilar of trastuzumab used for the treatment of Her2+ breast cancer; and respiratory system, cardiovascular system, dermatologic, endocrine and metabolism, and NSAI and myorelaxant products.
Abdi Ibrahim Ilaç Sanayi ve Ticaret A.S. was formerly known as Ibrahim Abdi Barut and changed its name to Abdi Ibrahim Ilaç Sanayi ve Ticaret A.S. in 1975. The company was founded in 1912 and is based in Istanbul, Turkey. It has operations in Kazakhstan, Algeria, Canada, and the United Kingdom.
Süha Taşpolatoğlu, CEO of Abdi Ibrahim, Turkish pharma’s “national champion”, discusses the company’s ambitious bet on biosimilars, their position as the licensing and CMO partner of choice for multinational companies…
Abdi İbrahim Otsuka, the Turkish-Japanese hybrid pharmaceutical company, celebrated their five-year anniversary just last year and have ambitions to become the Number One Japanese company in Turkey. Elif Elkin, in…
Turkey’s leading pharmaceutical company is in the process of developing production facilities abroad, and it has just begun construction of a USD 100 million biotech facility; CEO Süha Taşpolatoğlu believes…
The managing director of Otsuka’s 50-50 joint venture with Turkish giant Abdi Ibrahim, Abdi Ibrahim Otsuka, discusses the mutual advantage the companies can offer each other, and branding Abdi Ibrahim…
Ufuk S. Kumrulu, general manager of Polifarma, and Vildan Kumrulu, member of the board, share how the company has strategized its internal investments in recent years and how it plans…
M. Sonay Gürgen, chairman of the board and general manager of Selçuk Ecza Deposu, Turkey’s largest pharma distributory, offers his insider take on the pharmaceutical value chain in Turkey, the…
Dr. Altan Demirdere, president of Novartis Group in Turkey discusses the long history of Novartis and Sandoz in the country, as well as the current issues between the Turkish pharmaceutical…
Maria Fernanda Prado, managing director of Janssen Turkey, elaborates on the unique dynamics at play in Turkey; an important emerging market. Prado addresses the challenges, advantages, and opportunities that exist…
Philipp Haas, chairman and CEO of DEVA, discusses the company’s export strategy and current positioning in the international pharmaceutical playing field. Haas also covers the changing dynamics of the industry…
Turgut Tokgöz, secretary general of the Pharmaceutical Manufacturers Association of Turkey (IEIS), provides his take on the state of the Turkish pharmaceutical sector, highlighting the challenges that the industry faces…
Dr Orhan Mutlu Topal, general manager at Emre Ecza Ilac, offers an insider take on the Turkish vaccine industry, the challenges on the horizon for the Turkish pharmaceutical sector, and the…
Cem Kolak, founder and managing director of BL Turkey, the only Turkish Third Party Logistics (3PL) firm 100 percent dedicated to the biopharmaceutical and life sciences sectors, leverages his pioneering…
Meri Istiroti, group coordinator of Liv Hospital Group, shares the hospital’s success story since its beginning in 2013 to becoming a leading private healthcare institution dedicated to service, quality, and…
Emin Çakmak, chairman of the Turkish Healthcare Travel Council, offers deep insights into the healthcare travel industry and how it stretches beyond the commonly used term of “medical tourism”. Çakmak…
Elif Çelik, executive vice president of the Healthcare Division of Eczacıbaşı Group, explains the rationale behind the group’s divestment of its generics arm and its new strategy to establish itself…
Ece Kaşıkçı, General Manager, Bristol-Myers Squibb (BMS) Turkey, outlines how BMS’ groundbreaking immuno-oncology therapy has proudly become the first product of its kind to be registered and reimbursed in the…
See our Cookie Privacy Policy Here
